… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer ™ RNA editing technology platform today announced … will then be available for approximately 30 days. About Axiomer ™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer ™ , which could potentially yield a new class of …
Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline
€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event.
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… we are excited by the potential of our next-generation Axiomer RNA editing technology. In addition to using this … this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and will develop selected genetic eye disease targets with Axiomer ® . The Company anticipates providing further …
Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when comparing active treatment and sham eyes to their corresponding contralateral eyes across multiple endpoints – Company plans to discuss findings with regulators and pr